NYSE:BHVNBiohaven Pharmaceutical Stock Price, Forecast & News

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BHVN stock has increased by 87.9% and is now trading at $74.14. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biohaven Pharmaceutical.

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Biohaven Pharmaceutical.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($2.39) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.46) by $0.07. The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $0.21 million. During the same quarter in the prior year, the company posted ($1.41) EPS. View Biohaven Pharmaceutical's earnings history.

11 brokerages have issued 12 month target prices for Biohaven Pharmaceutical's shares. Their forecasts range from $41.00 to $109.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $77.90 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price. View analysts' price targets for Biohaven Pharmaceutical.

News stories about BHVN stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Biohaven Pharmaceutical.

Some companies that are related to Biohaven Pharmaceutical include Merck KGaA (MKGAF), Beigene (BGNE), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Dr.Reddy's Laboratories (RDY), Mylan (MYL) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Advanced Micro Devices (AMD), Micron Technology (MU), Crispr Therapeutics (CRSP), Biopharmx (BPMX), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Netflix (NFLX).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.01%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View institutional ownership trends for Biohaven Pharmaceutical.

BHVN stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Envestnet Asset Management Inc.. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric. View insider buying and selling activity for Biohaven Pharmaceutical.

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BHVN stock can currently be purchased for approximately $74.14.

Biohaven Pharmaceutical has a market capitalization of $4.34 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.